These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7885354)

  • 1. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1995 Jan; 10(1):37-43. PubMed ID: 7885354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
    Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
    Harder S; Baas H; Demisch L; Simon E
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):355-62. PubMed ID: 9707348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
    Merello M; Leiguarda R
    Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral pharmacokinetics of apomorphine in humans.
    Gancher ST; Woodward WR; Boucher B; Nutt JG
    Ann Neurol; 1989 Aug; 26(2):232-8. PubMed ID: 2774511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.